OTCMKTS:BVNRYBAVARIAN NORDIC/S Stock Price, Forecast & News

$5.29

0.00 (0.00 %)

(As of 04/9/2020 04:00 PM ET)

Add

Compare

Today's Range

$5.29

Now: $5.29▼

$5.29

50-Day Range

$5.04

MA: $8.49▼

$12.25

52-Week Range

$5.04

Now: $5.29▼

$12.25

Volume13 shs

Average Volume509 shs

Market Capitalization$512.76 million

P/E RatioN/A

Dividend YieldN/A

Beta1.19

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus. In addition, the company develops MVA-BN HIV, a preclinical stage human immunodeficiency virus (HIV) vaccine candidate; MVA-BN HBV, a preclinical stage hepatitis B vaccine candidate; CV301 that is in various clinical trials for the treatment of bladder, colorecta, and pancreatic and colorectal cancers; and MVA-BN Brachyury that is in Phase II clinical trials for the treatment of chordoma and other metastatic cancers. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Kvistgård, Denmark.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for BAVARIAN NORDIC/S.

2.7 Community Rank

Outperform Votes
BAVARIAN NORDIC/S has received 178 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
BAVARIAN NORDIC/S has received 146 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
BAVARIAN NORDIC/S has received 54.94% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about BAVARIAN NORDIC/S and other stocks. Vote “Outperform” if you believe BVNRY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BVNRY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
BAVARIAN NORDIC/S does not currently pay a dividend.
Dividend Growth
BAVARIAN NORDIC/S does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BAVARIAN NORDIC/S insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Earnings Growth
Earnings for BAVARIAN NORDIC/S are expected to decrease by -228.30% in the coming year, from ($0.53) to $0.68 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BAVARIAN NORDIC/S is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BAVARIAN NORDIC/S is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BAVARIAN NORDIC/S has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.54 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:BVNRY

Previous Symbol

CUSIPN/A

CIKN/A

Webhttp://www.bavarian-nordic.com/

Phone45-3326-8383

Debt

Debt-to-Equity Ratio0.24

Current Ratio7.43

Quick Ratio7.08

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$79.30 million

Price / Sales6.47

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.56 per share

Price / Book1.49

Profitability

EPS (Most Recent Fiscal Year)($0.59)

Net Income$-57,330,000.00

Net Margins-72.61%

Return on Equity-19.55%

Return on Assets-14.39%

Miscellaneous

Employees419

Outstanding Shares96,930,000

Market Cap$512.76 million

Next Earnings Date5/27/2020 (Estimated)

OptionableNot Optionable

Receive BVNRY News and Ratings via Email

Sign-up to receive the latest news and ratings for BVNRY and its competitors with MarketBeat's FREE daily newsletter.

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) Frequently Asked Questions

How has BAVARIAN NORDIC/S's stock been impacted by COVID-19 (Coronavirus)?

BAVARIAN NORDIC/S's stock was trading at $9.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BVNRY shares have decreased by 41.2% and is now trading at $5.29. View which stocks have been most impacted by Coronavirus.

When is BAVARIAN NORDIC/S's next earnings date?

BAVARIAN NORDIC/S is scheduled to release its next quarterly earnings announcement on Wednesday, May 27th 2020. View our earnings forecast for BAVARIAN NORDIC/S.

Has BAVARIAN NORDIC/S been receiving favorable news coverage?

News articles about BVNRY stock have trended very negative recently, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BAVARIAN NORDIC/S earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutBAVARIAN NORDIC/S.

Who are some of BAVARIAN NORDIC/S's key competitors?

Some companies that are related to BAVARIAN NORDIC/S include Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), Coherus Biosciences (CHRS), Regenxbio (RGNX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Cortexyme (CRTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), I-Mab (BDTX), Adverum Biotechnologies (ADVM), Beam Therapeutics (BEAM), Sangamo Therapeutics (SGMO) and Novavax (NVAX).

What other stocks do shareholders of BAVARIAN NORDIC/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BAVARIAN NORDIC/S investors own include Genmab A/S (GNMSF), Centerstate Bank (CSFL), Denny's (DENN), Rent-A-Center (RCII), Unity Biotechnology (UBX), Acceleron Pharma (XLRN), ABIOMED (ABMD), AC Immune (ACIU), Automatic Data Processing (ADP) and Aimmune Therapeutics (AIMT).

Who are BAVARIAN NORDIC/S's key executives?

BAVARIAN NORDIC/S's management team includes the following people:

Dr. Paul Chaplin, CEO & Pres (Age 52)
Mr. Henrik Juuel, CFO & Exec. VP (Age 54)
Mr. Henrik Birk, COO & Exec. VP (Age 45)
Dr. Tommi Kainu, Exec. VP & Chief Bus. Officer (Age 46)
Dr. Christopher R. Heery, Chief Medical Officer

What is BAVARIAN NORDIC/S's stock symbol?

BAVARIAN NORDIC/S trades on the OTCMKTS under the ticker symbol "BVNRY."

How do I buy shares of BAVARIAN NORDIC/S?

Shares of BVNRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BAVARIAN NORDIC/S's stock price today?

One share of BVNRY stock can currently be purchased for approximately $5.29.

How big of a company is BAVARIAN NORDIC/S?

BAVARIAN NORDIC/S has a market capitalization of $512.76 million and generates $79.30 million in revenue each year. The company earns $-57,330,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. BAVARIAN NORDIC/S employs 419 workers across the globe. View additional information about BAVARIAN NORDIC/S.

What is BAVARIAN NORDIC/S's official website?

The official website for BAVARIAN NORDIC/S is http://www.bavarian-nordic.com/.

How can I contact BAVARIAN NORDIC/S?

BAVARIAN NORDIC/S's mailing address is Hejreskovvej 10A, Kvistgaard G7, 3490. The company can be reached via phone at 45-3326-8383 or via email at [email protected]

This page was last updated on 4/9/2020 by MarketBeat.com Staff

Featured Article: Understanding Price to Earnings Ratio (PE)